中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
24期
11513-11517
,共5页
马春燕%王振国%万广志%赵爱华%梁玉梅%宋晶莹
馬春燕%王振國%萬廣誌%趙愛華%樑玉梅%宋晶瑩
마춘연%왕진국%만엄지%조애화%량옥매%송정형
子宫内膜异位症%血管抑制素类%血管生成抑制剂%大鼠
子宮內膜異位癥%血管抑製素類%血管生成抑製劑%大鼠
자궁내막이위증%혈관억제소류%혈관생성억제제%대서
Endometriosis%Angiostatins%Angiogenesis inhibitors%Rats
目的：分析重组人血管内皮抑制素注射液（恩度）对大鼠子宫内膜异位症新生血管的抑制效果，探索治疗子宫内膜异位症的新手段。方法自体移植法建立子宫内膜异位症动物模型，将子宫内膜异位症大鼠随机分为对照组（腹腔注射等体积生理盐水）、恩度高剂量组（2 mg·kg-1·d-1）、恩度低剂量组（1 mg·kg-1·d-1）。用药治疗2周后，测量异位病灶体积变化，血清中血管内皮生长因子（VEGF）含量，免疫组化法检测异位内膜、正常内膜、在位内膜组织中VEGF表达。结果与对照组相比，恩度治疗组大鼠异位内膜体积缩小，血清中VEGF含量降低，内膜组织中VEGF表达下降，差异有统计学意义（P＜0.05）。结论重组人血管内皮抑制素对正常免疫状态大鼠（Wistar大鼠）异位内膜组织新生血管的形成和病灶生长有明显抑制作用，恩度高剂量组治疗大鼠子宫内膜异位症效果更明显。
目的：分析重組人血管內皮抑製素註射液（恩度）對大鼠子宮內膜異位癥新生血管的抑製效果，探索治療子宮內膜異位癥的新手段。方法自體移植法建立子宮內膜異位癥動物模型，將子宮內膜異位癥大鼠隨機分為對照組（腹腔註射等體積生理鹽水）、恩度高劑量組（2 mg·kg-1·d-1）、恩度低劑量組（1 mg·kg-1·d-1）。用藥治療2週後，測量異位病竈體積變化，血清中血管內皮生長因子（VEGF）含量，免疫組化法檢測異位內膜、正常內膜、在位內膜組織中VEGF錶達。結果與對照組相比，恩度治療組大鼠異位內膜體積縮小，血清中VEGF含量降低，內膜組織中VEGF錶達下降，差異有統計學意義（P＜0.05）。結論重組人血管內皮抑製素對正常免疫狀態大鼠（Wistar大鼠）異位內膜組織新生血管的形成和病竈生長有明顯抑製作用，恩度高劑量組治療大鼠子宮內膜異位癥效果更明顯。
목적：분석중조인혈관내피억제소주사액（은도）대대서자궁내막이위증신생혈관적억제효과，탐색치료자궁내막이위증적신수단。방법자체이식법건립자궁내막이위증동물모형，장자궁내막이위증대서수궤분위대조조（복강주사등체적생리염수）、은도고제량조（2 mg·kg-1·d-1）、은도저제량조（1 mg·kg-1·d-1）。용약치료2주후，측량이위병조체적변화，혈청중혈관내피생장인자（VEGF）함량，면역조화법검측이위내막、정상내막、재위내막조직중VEGF표체。결과여대조조상비，은도치료조대서이위내막체적축소，혈청중VEGF함량강저，내막조직중VEGF표체하강，차이유통계학의의（P＜0.05）。결론중조인혈관내피억제소대정상면역상태대서（Wistar대서）이위내막조직신생혈관적형성화병조생장유명현억제작용，은도고제량조치료대서자궁내막이위증효과경명현。
Objective To analysis the effect of Recombinant Human Endostatin Injection (endostar)on angiogenesis in EMs rat, in order to explore a new treatment method of EMs. Methods EMs rats model were established by autologous transplantation methods.Then the rats were randomly divided into control groups received 0.9%NS by intraperitoneal injection, and the treatment group received endostar as above(The endostar high doses group received endostar 2 mg·kg-1·d-1, The endostar low doses group received endostar 1 mg·kg-1·d-1). The treatment regimen lasted 2 weeks.The volumes of EMs lesion and the levels of Serum VEGF were detected. Immunohistochemistry was used to determine the expression of VEGF in ectopic endometrium, normal endometrium and eutopic endometrium. Results Compared with the control group, the volumes of EMs lesion, the VEGF of Serum and endometrial tissue were decrease in the endostar treatment group. It is more obvious of endostar high doses group(P<0.05). Conclusion Recombinant Human Endostatin Injection can effectively interfere with the maintenance and grouth of endometriosis by inhibiting angiogenesis, and endostatin can reduce the expression of VEGF in endometrial tissue of EMs rats with Normal immune system (Wistar rats), it is more obvious of endostar high doses group.
